TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
TELA Bio, Inc. (NASDAQ: TELA), a medical technology company specializing in soft-tissue reconstruction solutions, has announced the approval of inducement grants by its Board of Directors' Compensation Committee. These grants, issued on August 6, 2024, consist of restricted stock units covering 16,000 shares of common stock, awarded to nine newly-hired employees.
The grants were made under the Nasdaq Rule 5635(c)(4) inducement grant exception, serving as a component of employment compensation and an incentive for accepting positions with TELA Bio. The restricted stock units will vest in equal annual installments over four years, contingent on continued service with the company.
TELA Bio, Inc. (NASDAQ: TELA), un’azienda tecnologica medica specializzata in soluzioni per la ricostruzione dei tessuti molli, ha annunciato l'approvazione di sovvenzioni incentivanti da parte del Comitato per la compensazione del suo Consiglio di Amministrazione. Queste sovvenzioni, emesse il 6 agosto 2024, consistono in unità azionarie vincolate relative a 16.000 azioni di azioni ordinarie, assegnate a nove nuovi dipendenti.
Le sovvenzioni sono state concesse ai sensi dell'eccezione per sovvenzioni incentivanti della Regola Nasdaq 5635(c)(4), fungendo da componente della compensazione ai fini dell'impiego e come incentivo per accettare le posizioni presso TELA Bio. Le unità azionarie vincolate maturi in rate annuali uguali nell’arco di quattro anni, a condizione di un servizio continuo presso l'azienda.
TELA Bio, Inc. (NASDAQ: TELA), una compañía de tecnología médica especializada en soluciones de reconstrucción de tejidos blandos, ha anunciado la aprobación de subvenciones de incentivo por parte del Comité de Compensación de su Junta Directiva. Estas subvenciones, emitidas el 6 de agosto de 2024, consisten en unidades de acciones restringidas que cubren 16,000 acciones de acciones comunes, otorgadas a nueve nuevos empleados.
Las subvenciones se realizaron bajo la excepción de subvenciones de incentivo de la Regla 5635(c)(4) de Nasdaq, sirviendo como un componente de la compensación laboral y un incentivo para aceptar puestos en TELA Bio. Las unidades de acciones restringidas se consolidarán en cuotas anuales iguales durante cuatro años, dependiendo del servicio continuo con la empresa.
TELA Bio, Inc. (NASDAQ: TELA), 연조직 재건 솔루션을 전문으로 하는 의료 기술 회사가 이사회의 보상 위원회에 의해 유도 보조금 승인을 발표했습니다. 이 보조금은 2024년 8월 6일에 발행되었으며, 16,000주의 보통주를 포함하는 제한 주식 단위로 신규 채용된 아홉 명의 직원에게 수여됩니다.
이 보조금은 나스닥 규칙 5635(c)(4)의 유도 보조금 예외에 따라 지급되며, TELA Bio에 채용될 때의 보상 요소로 기능합니다. 제한 주식 단위는 4년 동안 매년 동등하게 배분되어 회사에서 계속 근무하는 조건으로 행사됩니다.
TELA Bio, Inc. (NASDAQ: TELA), une entreprise de technologie médicale spécialisée dans les solutions de reconstruction des tissus mous, a annoncé l'approbation de subventions d'incitation par le comité de rémunération de son conseil d'administration. Ces subventions, émises le 6 août 2024, consistent en des unités d'actions restreintes couvrant 16 000 actions ordinaires, attribuées à neuf nouveaux employés.
Les subventions ont été accordées dans le cadre de l'exception de subventions d'incitation de la règle 5635(c)(4) de Nasdaq, servant de composant de la rémunération des employés et d'incitation à accepter des postes chez TELA Bio. Les unités d'actions restreintes s'incarneront en parts égales sur une période de quatre ans, sous réserve d'un service continu au sein de l'entreprise.
TELA Bio, Inc. (NASDAQ: TELA), ein Medizintechnologieunternehmen, das sich auf Lösungen zur Rekonstruktion von Weichgewebe spezialisiert hat, gab die Genehmigung von Anreizgewährungen durch den Vergütungsausschuss des Vorstands bekannt. Diese Gewährungen, die am 6. August 2024 ausgegeben wurden, bestehen aus beschränkten Aktieneinheiten, die 16.000 Aktien ordentlicher Aktien abdecken, die neun neu eingestellten Mitarbeitern zugewiesen wurden.
Die Gewährungen wurden gemäß der Nasdaq-Regel 5635(c)(4) unter der Ausnahme für Anreizvergaben vorgenommen und dienen als Bestandteil der Beschäftigungsvergütung und Anreiz zur Annahme von Stellen bei TELA Bio. Die beschränkten Aktieneinheiten werden über vier Jahre in gleichen jährlichen Raten fällig, vorausgesetzt, dass der Dienst bei der Gesellschaft fortgesetzt wird.
- Attraction of new talent with stock-based compensation
- Alignment of employee interests with company performance through equity grants
- Potential dilution of existing shareholders' equity
MALVERN, Pa., Aug. 09, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Compensation Committee of the Board of Directors of TELA Bio approved inducement grants of restricted stock units covering 16,000 shares of its common stock to nine newly-hired employees, with a grant date of August 6, 2024 (the "Grant Date"). The restricted stock units were granted pursuant to the Nasdaq Rule 5635(c)(4) inducement grant exception as a component of each individual's employment compensation and were granted as an inducement material to his or her acceptance of employment with TELA Bio.
The restricted stock units will vest in equal annual installments over four years, subject to each individual's continued service with TELA Bio through the applicable vesting dates.
About TELA Bio, Inc.
TELA Bio, Inc. (NASDAQ: TELA) is a commercial-stage medical technology company focused on providing innovative technologies that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's own anatomy. The Company is committed to providing surgeons with advanced, economically effective soft-tissue reconstruction solutions that leverage the patient's natural healing response while minimizing long-term exposure to permanent synthetic materials. For more information, visit www.telabio.com.
Caution Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations are forward-looking statements and reflect the current beliefs of TELA Bio's management. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and other factors that could cause actual results and events to differ materially and adversely from those indicated by such forward-looking statements. These risks and uncertainties are described more fully in the "Risk Factors" section and elsewhere in our filings with the Securities and Exchange Commission and available at www.sec.gov, including in our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Any forward-looking statements that we make in this announcement speak only as of the date of this press release, and TELA Bio assumes no obligation to update forward-looking statements whether as a result of new information, future events or otherwise after the date of this press release, except as required under applicable law.
Investor Contact
Greg Chodaczek
332-895-3230
ir@telabio.com
FAQ
How many shares of TELA Bio (TELA) were granted as restricted stock units on August 6, 2024?
What is the vesting schedule for the restricted stock units granted by TELA Bio (TELA)?
How many new employees received inducement grants from TELA Bio (TELA) in August 2024?
Under which Nasdaq rule were the inducement grants made by TELA Bio (TELA)?
